58278 Federal Register / Vol. 88, No. 164 / Friday, August 25, 2023 / Notices 

• Mail: Ms. Stephanie Thomas, ACIP 

Meeting, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

Mailstop H24–8, Atlanta, Georgia 

30329–4027. Attn: Docket No. CDC– 

2023–0060. 

Instructions: All submissions received 

must include the Agency name and 

docket number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

The meeting will be webcast live via 

the World Wide Web. The webcast link 

can be found on the ACIP website at 

https://www.cdc.gov/vaccines/acip/ 

index.html. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Stephanie Thomas, Committee 

Management Specialist, Advisory 

Committee on Immunization Practices, 

National Center for Immunization and 

Respiratory Diseases, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop H24–8, 

Atlanta, Georgia 30329–4027. 

Telephone: (404) 639–8836; Email: 

ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Advisory Committee on 

Immunization Practices (ACIP) is 

charged with advising the Director, 

Centers for Disease Control and 

Prevention (CDC), on the use of 

immunizing agents. In addition, under 

42 U.S.C. 1396s, the Committee is 

mandated to establish and periodically 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines For Children program, along 

with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under applicable provisions of the 

Affordable Care Act and section 2713 of 

the Public Health Service Act, 

immunization recommendations of 

ACIP that have been approved by the 

Director, CDC, and appear on CDC 

immunization schedules generally must 

be covered by applicable health plans. 

Matters To Be Considered: The agenda 

will include discussion of COVID–19 

vaccines. Recommendation votes for 

COVID–19 vaccines are scheduled. 

Agenda items are subject to change as 

priorities dictate. For more information 

on the meeting agenda, visit https://

www.cdc.gov/vaccines/acip/meetings/ 

index.html. 

Meeting Information: The meeting 

will be webcast live via the World Wide 

Web. For more information on ACIP, 

please visit the ACIP website: https://

www.cdc.gov/vaccines/acip/index.html. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near-duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: The docket 

will be opened to receive written 

comments on August 25, 2023. Written 

comments must be received by 

September 8, 2023. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. 

Priority will be given to individuals 

who submit a request to make an oral 

public comment before the meeting 

according to the procedures below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the September 12, 

2023, ACIP meeting must submit a 

request at https://www.cdc.gov/ 

vaccines/acip/meetings/index.html no 

later than 11:59 p.m., EDT, September 8, 

2023, according to the instructions 

provided. 

If the number of persons requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

time, CDC will conduct a lottery to 

determine the speakers for the 

scheduled public comment session. 

CDC staff will notify individuals 

regarding their request to speak by email 

on September 11, 2023. To 

accommodate the significant interest in 

participation in the oral public 

comment session of ACIP meetings, 

each speaker will be limited to three 

minutes, and each speaker may only 

speak once per meeting. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–18288 Filed 8–24–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60–Day–23–23HS; Docket No. CDC–2023– 

0074] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled Program Evaluation for PS22– 

2208 Component 2. This information 

collection request is designed to 

monitor and evaluate the PS22–2208 

Component 2 funding opportunity’s 

overall goal of supporting syringe 

services program (SSP) subrecipients in 

meeting the needs of people who use 

drugs (PWUD) and reducing infectious 

disease and other harms related to drug 

use during the 5-year PS22–2208 

Cooperative Agreement. 

DATES: CDC must receive written 

comments on or before October 24, 

2023. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2023– 

0074 by either of the following methods: 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 164 / Friday, August 25, 2023 / Notices 58279 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires Federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Program Evaluation for PS22–2208 

Component 2—New—National Center 

for HIV, Viral Hepatitis, STD, and TB 

Prevention (NCHHSTP), Centers for 

Disease Control and Prevention, Centers 

for Disease Control and Prevention 

(CDC). 

Background and Brief Description 

PS22–2208 Component 2 

(Strengthening Syringe Services 

Programs) serves as a coordinated and 

accountable mechanism for distribution 

of funding to syringe services programs 

(SSPs) to support implementation and 

expansion of services in areas of the 

United States, Territories, and Tribal 

Nations disproportionately affected by 

infectious disease consequences of 

injection drug use. Project activities will 

directly contribute to establishing and 

expanding a national SSP infrastructure 

and prevention of infectious disease 

consequences of drug use. CDC has 

funded the National Alliance of State 

and Territorial AIDs Directors 

(NASTAD) to implement this project. 

NASTAD, in partnership with 

University of Washington will collect 

monitoring and evaluation data from 

funded SSPs through their internal 

mechanisms, both for their internal 

evaluation as well as to report semiannual and annual project performance 

reports and stratified aggregate data to 

CDC. 

The primary purpose of this 

information collection is to monitor and 

evaluate the PS22–2208 Component 2 

funding opportunity’s overall goal of 

supporting SSP subrecipients in 

meeting the needs of people who use 

drugs (PWUD) and reducing infectious 

disease and other harms related to drug 

use. During the first year of this 

Cooperative Agreement, all PS22–2208 

SSP subrecipients will be sent a 25- 

minute baseline program evaluation 

survey at the start of project 

implementation, and a 15-minute 

quarterly program evaluation survey in 

the following three quarters of the 

project period. For Years 2–5, new 

PS22–2208 SSP subrecipients will be 

sent the baseline survey at the start of 

project implementation, and all existing 

subrecipients will receive the quarterly 

program evaluation survey in the 

following three quarters of the project 

period. SSP subrecipients will primarily 

complete the survey online in REDCap, 

with options to complete via telephone 

or videoconferencing modalities. 

Subrecipients will be asked to complete 

the surveys within one month of receipt 

and will receive weekly reminders until 

the survey is completed. SSP 

subrecipients may be reminded 

informally during meetings with 

NASTAD and may also work with their 

NASTAD point-of-contact to determine 

an alternate method of survey 

completion. The survey will include 

questions on operational and 

programmatic characteristics, and 

quantity of prevention and treatment 

services provided in-person, through 

tele-health, and through navigation to 

off-site care, during the specified 

evaluation period. 

Approximately 200 SSPs will 

participate in the survey. We estimate 

that it will take 70 minutes to complete 

the baseline survey and three quarterly 

surveys, regardless of how the 

respondent chooses to complete it (i.e., 

self-administered online or NASTAD 

staff-administered by phone or 

videoconferencing). CDC requests OMB 

approval for an estimated 233 annual 

burden hours. There is no cost to survey 

participants other than their time. 

ESTIMATES OF ANNUALIZED BURDEN HOURS

Respondent Form Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(hours) 

Total burden 

(in hours) 

All participating SSPs ............ Strengthening Syringe Services Programs 

Baseline Survey.

200 1 25/60 83 

All participating SSPs ............ Strengthening Syringe Services Programs 

Quarterly Survey.

200 3 15/60 150 


ddrumheller on DSK120RN23PROD with NOTICES1
58280 Federal Register / Vol. 88, No. 164 / Friday, August 25, 2023 / Notices 

ESTIMATES OF ANNUALIZED BURDEN HOURS—Continued 

Respondent Form Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(hours) 

Total burden 

(in hours) 

Total ............................... ....................................................................... ........................ ........................ ........................ 233 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2023–18363 Filed 8–24–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–23–1309] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘Enterprise 

Laboratory Information Management 

System’’ to the Office of Management 

and Budget (OMB) for review and 

approval. CDC previously published a 

‘‘Proposed Data Collection Submitted 

for Public Comment and 

Recommendations’’ notice on June 09, 

2023, to obtain comments from the 

public and affected agencies. CDC did 

not receive comments related to the 

previous notice. This notice serves to 

allow an additional 30 days for public 

and affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Enterprise Laboratory Information 

Management System (OMB Control No. 

0920–1309, Exp. 11/30/2023)— 

Revision—National Center for Emerging 

and Zoonotic Infectious Diseases 

(NCEZID), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The collection of specimen 

information designated for testing by the 

CDC occurs on a regular and recurring 

basis (multiple times per day) using an 

electronic PDF file called the CDC 

Specimen Submission 50.34 Form or an 

electronic XSLX file called the Global 

File Accessioning Template. Hospitals, 

doctor’s offices, medical clinics, 

commercial testing labs, universities, 

state public health laboratories, U.S. 

Federal institutions and foreign 

institutions use the CDC Specimen 

Submission 50.34 Form when 

submitting a single specimen to CDC 

Infectious Diseases laboratories for 

testing. The CDC Specimen Submission 

50.34 Form consists of over 200 data 

entry fields (of which five are 

mandatory fields that must be 

completed by the submitter) that 

captures information about the 

specimen being sent to the CDC for 

testing. The type of data captured on the 

50.34 Form identifies the origin of the 

specimen (human, animal, food, 

environmental, medical device or 

biologic), CDC test order name/code, 

specimen information, patient 

information (as applicable), animal 

information (as applicable) information 

about the submitting organization 

requesting the testing, patient history (as 

applicable), owner information and 

animal history (as applicable) and 

epidemiological information. The 

collection of this type of data is 

pertinent in ensuring a specimen’s 

testing results are linked to the correct 

patient and the final test reports are 

delivered to the appropriate submitting 

organization to aid in making proper 

health-related decisions related to the 

patient. Furthermore, the data provided 

on this form may be used by the CDC 

to identify sources of potential 

outbreaks and other public-health 

related events. When the form is filled 

out, a user in the submitting 

organization prints a hard copy of it that 

will be included in the specimen’s 

shipping package sent to the CDC. The 

printed form has barcodes on it that 

allow the CDC testing laboratory to scan 

its data directly into ELIMS where the 

specimen’s testing lifecycle is tracked 

and managed. 

Likewise, the Global File 

Accessioning Template records the 

same data as the 50.34 Form but 

provides the capability to submit 

information for a batch of specimens 

(typically 50–1,000 specimens per 

batch) to a specific CDC laboratory for 

testing. The CDC testing laboratory 

electronically uploads the Global File 

Accessioning Template into ELIMS 

where the batch of specimens are then 

logged and are ready to be tracked 

through their respective testing and 

reporting workflow. 

CDC requests OMB approval for an 

estimated 2,153 annualized burden 

hours. There is no cost to respondents 

other than their time to participate. 


ddrumheller on DSK120RN23PROD with NOTICES1